1. Home
  2. RIGL vs IRS Comparison

RIGL vs IRS Comparison

Compare RIGL & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rigel Pharmaceuticals Inc.

RIGL

Rigel Pharmaceuticals Inc.

N/A

Current Price

$39.76

Market Cap

911.8M

Sector

Health Care

ML Signal

N/A

Logo IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

IRS

IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

N/A

Current Price

$10.73

Market Cap

990.7M

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
RIGL
IRS
Founded
1996
1943
Country
United States
Argentina
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
911.8M
990.7M
IPO Year
2000
1998

Fundamental Metrics

Financial Performance
Metric
RIGL
IRS
Price
$39.76
$10.73
Analyst Decision
Buy
Buy
Analyst Count
4
3
Target Price
★ $64.40
$21.87
AVG Volume (30 Days)
204.0K
★ 271.7K
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
★ 13.59%
EPS Growth
★ 1867.68
N/A
EPS
★ 1.97
N/A
Revenue
★ $294,282,000.00
N/A
Revenue This Year
$5.32
N/A
Revenue Next Year
$24.14
$7.14
P/E Ratio
$21.00
★ $3.66
Revenue Growth
★ 64.15
N/A
52 Week Low
$24.84
$10.85
52 Week High
$52.61
$19.14

Technical Indicators

Market Signals
Indicator
RIGL
IRS
Relative Strength Index (RSI) 34.58 27.45
Support Level $37.60 N/A
Resistance Level $43.74 $16.10
Average True Range (ATR) 2.72 0.61
MACD -0.62 -0.17
Stochastic Oscillator 15.98 6.90

Price Performance

Historical Comparison
RIGL
IRS

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

IRSA Inversiones y Representaciones SA is a real estate company. Its segments are Shopping Malls which includes the operating results from its portfolio of shopping malls principally comprising lease and service revenue from tenants; Offices segment includes the operating results from lease revenue of offices; Hotels segment includes the operating results of its hotels mainly comprised of room, catering and restaurant revenue; Sales and Developments segment includes the results generated by other rental properties, the development, maintenance and sales of undeveloped parcels of land and/or trading properties; and Others segment includes the entertainment activities. Majority of revenue comes from Shopping Malls segment.

Share on Social Networks: